A randomized, controlled trial has shown human papillomavirus (HPV) DNA testing with and without liquid-based cytology to be more sensitive but less specific than conventional Papanicolaou smears for detection of precancerous lesions of the cervix. The lead-time advantage of early detection of precancerous lesions by HPV DNA testing resulted in cervical cancer reduction; however, an increased detection of possibly regressive precancerous lesions could result in unnecessary treatment, especially in women aged 25–34 years.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Ronco, G. et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 11, 249–257 (2010).
Bulkmans, N. W. et al Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet. 370, 1764–1772 (2007).
Sankaranarayanan, R. et al. HPV screening for cervical cancer in rural India. N. Engl. J. Med. 360, 1385–1394 (2009).
Dillner, J. et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study [abstract]. BMJ 337, a1754 (2008).
Kitchener, H. C. et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol. 10, 672–682 (2009).
Stoler, M. H. & Schiffman, M. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA 285, 1500–1505 (2001).
Siebers, A. G. et al. Comparison of liquid-based cytology with conventional cytology for detection of cervical cancer precursors: a randomized controlled trial. JAMA 302, 1757–1764 (2009).
Meissner, H. I., Tiro, J. A., Yabroff, K. R., Haggstrom, D. A. & Coughlin, S. S. Too much of a good thing? Physician practices and patient willingness for less frequent pap test screening intervals. Med. Care 48, 249–259 (2010).
Yabroff, K. R. et al. Specialty differences in primary care physician reports of papanicolaou test screening practices: a national survey, 2006 to 2007. Ann. Intern. Med. 151, 602–611 (2009).
Saraiya, M., Martinez, G., Glaser, K. & Kulasingam, S. Pap testing and sexual activity among young women in the United States. Obstet. Gynecol. 114, 1213–1219 (2009).
Acknowledgements
Dr. Castle was supported by the Intramural Research Program of the NIH, National Cancer Institute. The opinions expressed do not necessarily represent the opinions or policies of the National Cancer Institute, the National Institutes of Health, the US Department of Health and Human Services, or the US Government.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Castle, P. HPV testing for cervical cancer: the good, the bad, and the ugly. Nat Rev Clin Oncol 7, 364–365 (2010). https://doi.org/10.1038/nrclinonc.2010.96
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2010.96